TrialLung cancer (Amsterdam, Netherlands)2018

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.

Edward B Garon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.